Literature DB >> 7858860

Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery.

A Hatano1, H Takahashi, M Tamaki, T Komeyama, T Koizumi, M Takeda.   

Abstract

1. The alpha 1-adrenoceptor subtypes mediating contractions of the smooth muscle in human prostatic urethra and branches of internal iliac artery were characterized in isometric contraction experiments. 2. Phenylephrine produced concentration-dependent contractions in both the urethra and artery. These responses were competitively inhibited by prazosin, WB4101 and 5-methyl-urapidil, and the slopes of Schild plots for all these antagonists were close to unity. 3. The pA2 values for prazosin were not significantly different between the urethra (9.42 +/- 0.11; mean +/- s.d.) and artery (9.50 +/- 0.27), while the pA2 values for WB4101 and 5-methyl-urapidil in the human prostatic urethra (8.94 +/- 0.19 and 8.42 +/- 0.14, respectively) were significantly greater than in the branches of human internal iliac artery (7.94 +/- 0.21 and 7.43 +/- 0.22, respectively; P < 0.01). 4. Pretreatment with chlorethylclonidine (CEC) at concentrations ranging from 0.1 microM to 100 microM attenuated the maximum contraction to phenylephrine in a concentration-dependent manner in both the urethra and artery. However, the urethra was significantly less affected by CEC than the artery. The pD'2 values (negative logarithm of the molar concentration of antagonist which reduced the maximum contraction to one half) in the urethra and artery were 4.35 +/- 0.27 and 5.20 +/- 0.37, respectively (P < 0.01). 5. The present results indicate that there are distinct populations of alpha 1-adrenoceptor subtypes in the human prostatic urethra and branches of the internal iliac artery. The alpha 1-adrenoceptors responsible for the contraction of the human internal iliac artery branches are predominantly alpha 1 B-subtype, whereas those in the human prostatic urethra are considered to be not alpha 1 B, but alpha 1 c or possibly alpha 1 A or alpha 1A/D-subtype.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7858860      PMCID: PMC1510428          DOI: 10.1111/j.1476-5381.1994.tb17053.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

1.  Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck.

Authors:  M Caine; S Raz; M Zeigler
Journal:  Br J Urol       Date:  1975-04

2.  A pharmacological study of alpha adrenergic receptor subtypes in smooth muscle of human urinary bladder base and prostatic urethra.

Authors:  Y Kunisawa; K Kawabe; T Niijima; K Honda; T Takenaka
Journal:  J Urol       Date:  1985-08       Impact factor: 7.450

3.  Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding.

Authors:  A L Morrow; I Creese
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

4.  Studies on some para-substituted clonidine derivatives that exhibit an alpha-adrenoceptor stimulant activity.

Authors:  G Leclerc; B Rouot; J Schwartz; J Velly; C G Wermuth
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

5.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

6.  Sympathetic activity in the proximal urethra in patients with urinary obstruction.

Authors:  S A Awad; J W Downie; D W Lywood; R A Young; S V Jarzylo
Journal:  J Urol       Date:  1976-05       Impact factor: 7.450

7.  Effects of prazosin in patients with benign prostatic obstruction.

Authors:  H Hedlund; K E Andersson; A Ek
Journal:  J Urol       Date:  1983-08       Impact factor: 7.450

8.  Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy.

Authors:  S Furuya; Y Kumamoto; E Yokoyama; T Tsukamoto; T Izumi; Y Abiko
Journal:  J Urol       Date:  1982-10       Impact factor: 7.450

9.  The use of alpha-adrenergic blockers in benign prostatic obstruction.

Authors:  M Caine; A Pfau; S Perlberg
Journal:  Br J Urol       Date:  1976-08

10.  Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia.

Authors:  H Lepor; E Shapiro
Journal:  J Urol       Date:  1984-12       Impact factor: 7.450

View more
  18 in total

1.  Differential vascular alpha1-adrenoceptor antagonism by tamsulosin and terazosin.

Authors:  R F Schäfers; B Fokuhl; A Wasmuth; H Schumacher; K Taguchi; C de Mey; T Philipp; M C Michel
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

2.  The effects of SB 216469, an antagonist which discriminates between the alpha 1A-adrenoceptor and the human prostatic alpha 1-adrenoceptor.

Authors:  R Chess-Williams; C R Chapple; F Verfurth; A J Noble; C J Couldwell; M C Michel
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

3.  Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2009

4.  Different subtypes of alpha 1A-adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053.

Authors:  I Marshall; R P Burt; G M Green; M B Hussain; C R Chapple
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

5.  alpha(1)-Adrenoceptor subtypes in the mouse mesenteric artery and abdominal aorta.

Authors:  Y Yamamoto; K Koike
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

6.  In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists.

Authors:  T J Williams; D R Blue; D V Daniels; B Davis; T Elworthy; J R Gever; M S Kava; D Morgans; F Padilla; S Tassa; R L Vimont; C R Chapple; R Chess-Williams; R M Eglen; D E Clarke; A P Ford
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

7.  Functional characterization of alpha(1)-adrenoceptor subtypes in human skeletal muscle resistance arteries.

Authors:  Y P Jarajapu; P Coats; J C McGrath; C Hillier; A MacDonald
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

Review 8.  Silodosin is effective for treatment of LUTS in men with BPH: a systematic review.

Authors:  Hui Ding; Wan Du; Zi-Zhen Hou; Han-Zhang Wang; Zhi-Ping Wang
Journal:  Asian J Androl       Date:  2012-12-10       Impact factor: 3.285

9.  Effect of extended-term estrogen on voiding in a postpartum ovariectomized rat model.

Authors:  Narihiko Hayashi; Anthony J Bella; Guifang Wang; Guiting Lin; Donna Y Deng; Lora Nunes; Tom F Lue
Journal:  Can Urol Assoc J       Date:  2007-09       Impact factor: 1.862

Review 10.  A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia.

Authors:  J C Nickel; S Sander; T D Moon
Journal:  Int J Clin Pract       Date:  2008-10       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.